Kelley M. Swanberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kelley M. Swanberg has a total of 197 co-authors. Here are the top co-authors by number of shared publications:
Christoph Juchem
Department of Biomedical Engineering Columbia University Fu Foundation School of Engineering and Applied Science New York New York USA
9 shared publications- Karl Landheer
Regeneron Genetics Center Tarrytown New York USA
5 shared publications Hetty Prinsen
Radiology and Biomedical Imaging Yale University School of Medicine New Haven CT USA
4 shared publicationsAbhinav V. Kurada
Biomedical Engineering Columbia University School of Engineering and Applied Science New York NY USA
3 shared publications- Sungho Maeng
College of East-West Medical Science, Kyung Hee University, Yongin 17104, Republic of Korea
3 shared publications David Pitt
Department of Neurology Yale University School of Medicine New Haven Connecticut
2 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (12)
Synthetic Data in MR Spectroscopy: Current Practices, Applications, and Considerations
Synthetic data generation has become an increasingly important component of methodological development in magnetic resonance spectroscopy (MRS), particularly in contexts where ground‐truth in vivo measurements are limited, noisy, or inaccessible. This review provides a structured overview of current practices in synthetic MRS data generation, with emphasis on the physical, biochemical, and computational assumptions that underpin commonly used models. A decomposition of synthetic MRS data is presented in terms of core building blocks, including basis sets, signal formation models, and metabolite parameter distributions such as concentration and relaxation properties. This framework is extended to advanced components required for realistic data synthesis, including baseline and nuisance signals, spatial encoding effects such as coil sensitivities and field inhomogeneities, k‐space sampling and gradient imperfections, as well as sample‐specific and temporal dynamics. Beyond single‐voxel modeling, synthetic data generation across multiple MRS modalities is discussed, including functional MRS, diffusion‐weighted MRS, and spectroscopic imaging, with emphasis on modality‐specific challenges such as physiological variability, motion, and confounding signal contributions. The role of synthetic data in clinical and preclinical research, acquisition optimization, software validation, and emerging artificial intelligence applications is further examined, with particular attention to domain shift and representational realism. Current practices in validation, reporting standards, and data accessibility are also reviewed, and key gaps limiting reproducibility and interoperability across studies are identified. Overall, this work provides a unified conceptual framework for synthetic MRS data generation, clarifies underlying assumptions across modeling choices, and outlines open challenges toward improving realism, standardization, and utility in both methodological and translational applications. Conducted by the MRS Synthetic Data Working Group under the Code & Data Sharing Committee of the MRS Study Group of the International Society for Magnetic Resonance in Medicine (ISMRM), this review encompasses the existing literature, supplemented by the collective experience and in‐house methodologies of its contributors, providing a community perspective that extends beyond the published record.
- 17 November 2026
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (12)
Open AccessSynthetic Data in MR Spectroscopy: Current Practices, Applications, and Considerations
Synthetic data generation has become an increasingly important component of methodological development in magnetic resonance spectroscopy (MRS), particularly in contexts where ground‐truth in vivo measurements are limited, noisy, or inaccessible. This review provides a structured overview of current practices in synthetic MRS data generation, with emphasis on the physical, biochemical, and computational assumptions that underpin commonly used models. A decomposition of synthetic MRS data is presented in terms of core building blocks, including basis sets, signal formation models, and metabolite parameter distributions such as concentration and relaxation properties. This framework is extended to advanced components required for realistic data synthesis, including baseline and nuisance signals, spatial encoding effects such as coil sensitivities and field inhomogeneities, k‐space sampling and gradient imperfections, as well as sample‐specific and temporal dynamics. Beyond single‐voxel modeling, synthetic data generation across multiple MRS modalities is discussed, including functional MRS, diffusion‐weighted MRS, and spectroscopic imaging, with emphasis on modality‐specific challenges such as physiological variability, motion, and confounding signal contributions. The role of synthetic data in clinical and preclinical research, acquisition optimization, software validation, and emerging artificial intelligence applications is further examined, with particular attention to domain shift and representational realism. Current practices in validation, reporting standards, and data accessibility are also reviewed, and key gaps limiting reproducibility and interoperability across studies are identified. Overall, this work provides a unified conceptual framework for synthetic MRS data generation, clarifies underlying assumptions across modeling choices, and outlines open challenges toward improving realism, standardization, and utility in both methodological and translational applications. Conducted by the MRS Synthetic Data Working Group under the Code & Data Sharing Committee of the MRS Study Group of the International Society for Magnetic Resonance in Medicine (ISMRM), this review encompasses the existing literature, supplemented by the collective experience and in‐house methodologies of its contributors, providing a community perspective that extends beyond the published record.
- Open Access
A harmonized phantom MRI quality control framework identifies sources of longitudinal and multi-site variability
The shift towards open science in preclinical research requires high-quality, comparable data adhering to FAIR principles, yet rigorous quality assurance (QA) and quality control (QC) frameworks remain less established in preclinical magnetic resonance imaging (MRI) than in clinical imaging. To address this limitation, a multicenter study was conducted across 21 international laboratories using standardized commercial liquid phantoms for mouse and rat MRI setups and a harmonized acquisition protocol. Data processing was centralized using AIDAqc, an automated pipeline extracting quantitative metrics including signal-to-noise ratio (SNR), temporal SNR (tSNR), ghost-to-signal ratio (GSR), and motion-equivalent temporal instability, combined with five complementary outlier-detection algorithms. The evaluated datasets encompassed magnetic field strengths from 3.0 to 16.4 T and heterogeneous coil and acquisition configurations. In mouse phantom data, SNR and tSNR were significantly lower at 3 T than at 7 and 9.4 T, whereas artifact-related metrics did not differ significantly between field-strength groups. In rat phantom data, differences between field strengths were less pronounced. At 7 T, substantial dataset-specific differences were observed in anatomical and functional quality metrics, also among datasets using the similar coil configuration. Multicenter reference values for frequently represented 7 T configurations were established, including SNR/tSNR of 48 ± 3/48 ± 1 dB for mouse surface-coil datasets and 49 ± 3/44 ± 4 dB for rat 2 × 2 array-coil datasets. Longitudinal anatomical SNR showed generally low variability, whereas GSR was more variable across time. Automated outlier detection additionally identified transient acquisition instabilities that were not always apparent by visual inspection. Together, these findings show that field strength and nominal coil configuration alone do not adequately characterize MRI performance and support standardized, longitudinal phantom- based QC combined with automated analysis as a practical approach for improving the reliability, transparency, and interoperability of multicenter preclinical MRI data.
Open AccessA harmonized phantom MRI quality control framework identifies sources of longitudinal and multi-site variability
The shift towards open science in preclinical research requires high-quality, comparable data adhering to FAIR principles, yet rigorous quality assurance (QA) and quality control (QC) frameworks remain less established in preclinical magnetic resonance imaging (MRI) than in clinical imaging. To address this limitation, a multicenter study was conducted across 21 international laboratories using standardized commercial liquid phantoms for mouse and rat MRI setups and a harmonized acquisition protocol. Data processing was centralized using AIDAqc, an automated pipeline extracting quantitative metrics including signal-to-noise ratio (SNR), temporal SNR (tSNR), ghost-to-signal ratio (GSR), and motion-equivalent temporal instability, combined with five complementary outlier-detection algorithms. The evaluated datasets encompassed magnetic field strengths from 3.0 to 16.4 T and heterogeneous coil and acquisition configurations. In mouse phantom data, SNR and tSNR were significantly lower at 3 T than at 7 and 9.4 T, whereas artifact-related metrics did not differ significantly between field-strength groups. In rat phantom data, differences between field strengths were less pronounced. At 7 T, substantial dataset-specific differences were observed in anatomical and functional quality metrics, also among datasets using the similar coil configuration. Multicenter reference values for frequently represented 7 T configurations were established, including SNR/tSNR of 48 ± 3/48 ± 1 dB for mouse surface-coil datasets and 49 ± 3/44 ± 4 dB for rat 2 × 2 array-coil datasets. Longitudinal anatomical SNR showed generally low variability, whereas GSR was more variable across time. Automated outlier detection additionally identified transient acquisition instabilities that were not always apparent by visual inspection. Together, these findings show that field strength and nominal coil configuration alone do not adequately characterize MRI performance and support standardized, longitudinal phantom- based QC combined with automated analysis as a practical approach for improving the reliability, transparency, and interoperability of multicenter preclinical MRI data.
- Open Access
- 4 August 2026
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 49 (11)
The brain drain problem in sleep apnea
- 4 August 2026
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 49 (11)
Open AccessThe brain drain problem in sleep apnea
- 4 March 2025
- Published by Wiley in NMR in Biomedicine
- Vol. 38 (4) , e70010
Spline Baseline Model Flexibility Independently Affects the Accuracy and Precision of In Vivo Proton Magnetic Resonance Spectral Fitting in a Metabolite‐Specific Manner Not Visually Predicted by Fit Residuals
In vivo proton magnetic resonance spectroscopy (1H‐MRS) data often exhibit baselines or low‐amplitude signal variations resulting from residual water, imperfectly suppressed lipids, low‐amplitude metabolites not considered for fitting, and other features not represented in a basis set. While multitudinous approaches exist to model these baselines in 1H‐MR spectral analysis, many continue to lack systematic validation against varied and realistic ground‐truth standards. Here, we compare the accuracy (error mean) and precision (error standard deviation) of metabolite scaling estimates by linear combination modeling (LCM) spectral fitting accounting for spectral baselines via smoothed cubic splines at 50 different combinations of fixed knot interval and smoothing weight, either with or without additionally simulated Gaussian basis signals to separately model spectral macromolecules. Synthesized in‐vivo‐like metabolite brain spectra incorporating macromolecule signals measured using double‐inversion‐recovery‐prepared sLASER (TE 20.1 ms; TR 2 s; TI1 920 ms; TI2 330 ms) at 3 T from single voxels in the frontal and occipital cortex of 10 healthy volunteers (five female; 23 ± 5 y.o.) provided both in vivo realism and a standard ground truth for error calculation. Optimal baseline flexibility differed both by definition of “optimum” as either accuracy or precision and by metabolite. Regardless of definition or metabolite, optimal models were not those yielding the smallest fit residuals. Optimized spline baseline definitions yielded high accuracies (lowest mean error −0.003 ± 2.1% for total N‐acetyl aspartate and highest mean error 10.1 ± 19.2% for glutamate + glutamine within fits including macromolecule bases) as well as comparable precision for most metabolites to fits achieved in LCModel; inclusion of simulated macromolecules in baseline models improved maximum fit precision but not accuracy. Taken together, these data illustrate that optimized spline baseline model flexibility exhibits metabolite‐specific relationships with 1H‐MR spectral quantification accuracy or precision not readily predicted by visual inspection of associated fit residuals and not necessarily improved by adaptive relative to absolute constraints.
- 4 March 2025
- Published by Wiley in NMR in Biomedicine
- Vol. 38 (4) , e70010
Spline Baseline Model Flexibility Independently Affects the Accuracy and Precision of In Vivo Proton Magnetic Resonance Spectral Fitting in a Metabolite‐Specific Manner Not Visually Predicted by Fit Residuals
In vivo proton magnetic resonance spectroscopy (1H‐MRS) data often exhibit baselines or low‐amplitude signal variations resulting from residual water, imperfectly suppressed lipids, low‐amplitude metabolites not considered for fitting, and other features not represented in a basis set. While multitudinous approaches exist to model these baselines in 1H‐MR spectral analysis, many continue to lack systematic validation against varied and realistic ground‐truth standards. Here, we compare the accuracy (error mean) and precision (error standard deviation) of metabolite scaling estimates by linear combination modeling (LCM) spectral fitting accounting for spectral baselines via smoothed cubic splines at 50 different combinations of fixed knot interval and smoothing weight, either with or without additionally simulated Gaussian basis signals to separately model spectral macromolecules. Synthesized in‐vivo‐like metabolite brain spectra incorporating macromolecule signals measured using double‐inversion‐recovery‐prepared sLASER (TE 20.1 ms; TR 2 s; TI1 920 ms; TI2 330 ms) at 3 T from single voxels in the frontal and occipital cortex of 10 healthy volunteers (five female; 23 ± 5 y.o.) provided both in vivo realism and a standard ground truth for error calculation. Optimal baseline flexibility differed both by definition of “optimum” as either accuracy or precision and by metabolite. Regardless of definition or metabolite, optimal models were not those yielding the smallest fit residuals. Optimized spline baseline definitions yielded high accuracies (lowest mean error −0.003 ± 2.1% for total N‐acetyl aspartate and highest mean error 10.1 ± 19.2% for glutamate + glutamine within fits including macromolecule bases) as well as comparable precision for most metabolites to fits achieved in LCModel; inclusion of simulated macromolecules in baseline models improved maximum fit precision but not accuracy. Taken together, these data illustrate that optimized spline baseline model flexibility exhibits metabolite‐specific relationships with 1H‐MR spectral quantification accuracy or precision not readily predicted by visual inspection of associated fit residuals and not necessarily improved by adaptive relative to absolute constraints.
- 25 July 2024
- Published by Wiley in NMR in Biomedicine
- Vol. 37 (11) , e5220
Medial prefrontal cortex neurotransmitter abnormalities in posttraumatic stress disorder with and without comorbidity to major depression
Posttraumatic stress disorder (PTSD) is a chronic psychiatric condition that follows exposure to a traumatic stressor. Though previous in vivo proton (1H) MRS) research conducted at 4 T or lower has identified alterations in glutamate metabolism associated with PTSD predisposition and/or progression, no prior investigations have been conducted at higher field strength. In addition, earlier studies have not extensively addressed the impact of psychiatric comorbidities such as major depressive disorder (MDD) on PTSD‐associated 1H‐MRS‐visible brain metabolite abnormalities. Here we employ 7 T 1H MRS to examine concentrations of glutamate, glutamine, GABA, and glutathione in the medial prefrontal cortex (mPFC) of PTSD patients with MDD (PTSD+MDD+; N = 6) or without MDD (PTSD+MDD−; N = 5), as well as trauma‐unmatched controls without PTSD but with MDD (PTSD−MDD+; N = 9) or without MDD (PTSD−MDD−; N = 18). Participants with PTSD demonstrated decreased ratios of GABA to glutamine relative to healthy PTSD−MDD− controls but no single‐metabolite abnormalities. When comorbid MDD was considered, however, MDD but not PTSD diagnosis was significantly associated with increased mPFC glutamine concentration and decreased glutamate:glutamine ratio. In addition, all participants with PTSD and/or MDD collectively demonstrated decreased glutathione relative to healthy PTSD−MDD− controls. Despite limited findings in single metabolites, patterns of abnormality in prefrontal metabolite concentrations among individuals with PTSD and/or MDD enabled supervised classification to separate them from healthy controls with 80+% sensitivity and specificity, with glutathione, glutamine, and myoinositol consistently among the most informative metabolites for this classification. Our findings indicate that MDD can be an important factor in mPFC glutamate metabolism abnormalities observed using 1H MRS in cohorts with PTSD.
- 25 July 2024
- Published by Wiley in NMR in Biomedicine
- Vol. 37 (11) , e5220
Medial prefrontal cortex neurotransmitter abnormalities in posttraumatic stress disorder with and without comorbidity to major depression
Posttraumatic stress disorder (PTSD) is a chronic psychiatric condition that follows exposure to a traumatic stressor. Though previous in vivo proton (1H) MRS) research conducted at 4 T or lower has identified alterations in glutamate metabolism associated with PTSD predisposition and/or progression, no prior investigations have been conducted at higher field strength. In addition, earlier studies have not extensively addressed the impact of psychiatric comorbidities such as major depressive disorder (MDD) on PTSD‐associated 1H‐MRS‐visible brain metabolite abnormalities. Here we employ 7 T 1H MRS to examine concentrations of glutamate, glutamine, GABA, and glutathione in the medial prefrontal cortex (mPFC) of PTSD patients with MDD (PTSD+MDD+; N = 6) or without MDD (PTSD+MDD−; N = 5), as well as trauma‐unmatched controls without PTSD but with MDD (PTSD−MDD+; N = 9) or without MDD (PTSD−MDD−; N = 18). Participants with PTSD demonstrated decreased ratios of GABA to glutamine relative to healthy PTSD−MDD− controls but no single‐metabolite abnormalities. When comorbid MDD was considered, however, MDD but not PTSD diagnosis was significantly associated with increased mPFC glutamine concentration and decreased glutamate:glutamine ratio. In addition, all participants with PTSD and/or MDD collectively demonstrated decreased glutathione relative to healthy PTSD−MDD− controls. Despite limited findings in single metabolites, patterns of abnormality in prefrontal metabolite concentrations among individuals with PTSD and/or MDD enabled supervised classification to separate them from healthy controls with 80+% sensitivity and specificity, with glutathione, glutamine, and myoinositol consistently among the most informative metabolites for this classification. Our findings indicate that MDD can be an important factor in mPFC glutamate metabolism abnormalities observed using 1H MRS in cohorts with PTSD.
- Open Access
- 9 October 2022
- Published by SAGE Publications in Chronic Stress
- Vol. 6
Proton Magnetic Resonance Spectroscopy in Post-Traumatic Stress Disorder—Updated Systematic Review and Meta-Analysis
A stressor-related disorder wherein traumatic experience precipitates protracted disruptions to mood and cognition, post-traumatic stress disorder (PTSD) is associated with wide-ranging abnormalities across the body. While various methods have investigated these deviations, only proton magnetic resonance spectroscopy (1H MRS) enables noninvasive measurement of small-molecule metabolites in the living human. 1H MRS has correspondingly been employed to test hypotheses about the composition and function of multiple brain regions putatively involved in PTSD. Here we systematically review methodological considerations and reported findings, both positive and negative, of the current 1H-MRS literature in PTSD (N = 32 studies) to communicate the brain regional metabolite alterations heretofore observed, providing random-effects model meta-analyses for those most extensively studied. Our review suggests significant PTSD-associated decreases in N-acetyl aspartate in bilateral hippocampus and anterior cingulate cortex with less evident effect in other metabolites and regions. Model heterogeneities diverged widely by analysis (I2 < 0.01% to 90.1%) and suggested regional dependence on quantification reference (creatine or otherwise). While observed variabilities in methods and reported findings suggest that 1H-MRS explorations of PTSD could benefit from methodological standardization, informing this standardization by quantitative assessment of the existing literature is currently hampered by its small size and limited scope.
- 9 October 2022
- Published by SAGE Publications in Chronic Stress
- Vol. 6
Open AccessProton Magnetic Resonance Spectroscopy in Post-Traumatic Stress Disorder—Updated Systematic Review and Meta-Analysis
A stressor-related disorder wherein traumatic experience precipitates protracted disruptions to mood and cognition, post-traumatic stress disorder (PTSD) is associated with wide-ranging abnormalities across the body. While various methods have investigated these deviations, only proton magnetic resonance spectroscopy (1H MRS) enables noninvasive measurement of small-molecule metabolites in the living human. 1H MRS has correspondingly been employed to test hypotheses about the composition and function of multiple brain regions putatively involved in PTSD. Here we systematically review methodological considerations and reported findings, both positive and negative, of the current 1H-MRS literature in PTSD (N = 32 studies) to communicate the brain regional metabolite alterations heretofore observed, providing random-effects model meta-analyses for those most extensively studied. Our review suggests significant PTSD-associated decreases in N-acetyl aspartate in bilateral hippocampus and anterior cingulate cortex with less evident effect in other metabolites and regions. Model heterogeneities diverged widely by analysis (I2 < 0.01% to 90.1%) and suggested regional dependence on quantification reference (creatine or otherwise). While observed variabilities in methods and reported findings suggest that 1H-MRS explorations of PTSD could benefit from methodological standardization, informing this standardization by quantitative assessment of the existing literature is currently hampered by its small size and limited scope.
- Open Access
- 16 August 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-15
Multiple sclerosis diagnosis and phenotype identification by multivariate classification of in vivo frontal cortex metabolite profiles
Multiple sclerosis (MS) is a heterogeneous autoimmune disease for which diagnosis continues to rely on subjective clinical judgment over a battery of tests. Proton magnetic resonance spectroscopy (1H MRS) enables the noninvasive in vivo detection of multiple small-molecule metabolites and is therefore in principle a promising means of gathering information sufficient for multiple sclerosis diagnosis and subtype classification. Here we show that supervised classification using1H-MRS-visible normal-appearing frontal cortex small-molecule metabolites alone can indeed differentiate individuals with progressive MS from control (held-out validation sensitivity 79% and specificity 68%), as well as between relapsing and progressive MS phenotypes (held-out validation sensitivity 84% and specificity 74%). Post hoc assessment demonstrated the disproportionate contributions of glutamate and glutamine to identifying MS status and phenotype, respectively. Our finding establishes1H MRS as a viable means of characterizing progressive multiple sclerosis disease status and paves the way for continued refinement of this method as an auxiliary or mainstay of multiple sclerosis diagnostics.
- 16 August 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-15
Open AccessMultiple sclerosis diagnosis and phenotype identification by multivariate classification of in vivo frontal cortex metabolite profiles
Multiple sclerosis (MS) is a heterogeneous autoimmune disease for which diagnosis continues to rely on subjective clinical judgment over a battery of tests. Proton magnetic resonance spectroscopy (1H MRS) enables the noninvasive in vivo detection of multiple small-molecule metabolites and is therefore in principle a promising means of gathering information sufficient for multiple sclerosis diagnosis and subtype classification. Here we show that supervised classification using1H-MRS-visible normal-appearing frontal cortex small-molecule metabolites alone can indeed differentiate individuals with progressive MS from control (held-out validation sensitivity 79% and specificity 68%), as well as between relapsing and progressive MS phenotypes (held-out validation sensitivity 84% and specificity 74%). Post hoc assessment demonstrated the disproportionate contributions of glutamate and glutamine to identifying MS status and phenotype, respectively. Our finding establishes1H MRS as a viable means of characterizing progressive multiple sclerosis disease status and paves the way for continued refinement of this method as an auxiliary or mainstay of multiple sclerosis diagnostics.
- 28 July 2021
- Published by Wiley in NMR in Biomedicine
- Vol. 34 (11) , e4590
In vivo evidence of differential frontal cortex metabolic abnormalities in progressive and relapsing‐remitting multiple sclerosis
The pathophysiology of progressive multiple sclerosis remains elusive, significantly limiting available disease‐modifying therapies. Proton MRS (1H‐MRS) enables in vivo measurement of small molecules implicated in multiple sclerosis, but its application to key metabolites glutamate, γ‐aminobutyric acid (GABA), and glutathione has been sparse. We employed, at 7 T, a previously validated 1H‐MRS protocol to measure glutamate, GABA, and glutathione, as well as glutamine, N‐acetyl aspartate, choline, and myoinositol, in the frontal cortex of individuals with relapsing‐remitting (N = 26) or progressive (N = 21) multiple sclerosis or healthy control adults (N = 25) in a cross‐sectional analysis. Only individuals with progressive multiple sclerosis demonstrated reduced glutamate (F2,65 = 3.424, p = 0.04; 12.40 ± 0.62 mM versus control 13.17 ± 0.95 mM, p = 0.03) but not glutamine (F2,65 = 0.352, p = 0.7; 4.71 ± 0.35 mM versus control 4.84 ± 0.42 mM), reduced GABA (F2,65 = 3.89, p = 0.03; 1.29 ± 0.23 mM versus control 1.47 ± 0.25 mM, p = 0.05), and possibly reduced glutathione (F2,65 = 0.352, p = 0.056; 2.23 ± 0.46 mM versus control 2.51 ± 0.48 mM, p < 0.1). As a group, multiple sclerosis patients demonstrated significant negative correlations between disease duration and glutamate or GABA (ρ = −0.4, p = 0.02) but not glutamine or glutathione. Alone, only relapsing‐remitting multiple sclerosis patients exhibited a significant negative correlation between disease duration and GABA (ρ = −0.5, p = 0.03). Taken together, these results indicate that frontal cortex metabolism is differentially disturbed in progressive and relapsing‐remitting multiple sclerosis.
- 28 July 2021
- Published by Wiley in NMR in Biomedicine
- Vol. 34 (11) , e4590
In vivo evidence of differential frontal cortex metabolic abnormalities in progressive and relapsing‐remitting multiple sclerosis
The pathophysiology of progressive multiple sclerosis remains elusive, significantly limiting available disease‐modifying therapies. Proton MRS (1H‐MRS) enables in vivo measurement of small molecules implicated in multiple sclerosis, but its application to key metabolites glutamate, γ‐aminobutyric acid (GABA), and glutathione has been sparse. We employed, at 7 T, a previously validated 1H‐MRS protocol to measure glutamate, GABA, and glutathione, as well as glutamine, N‐acetyl aspartate, choline, and myoinositol, in the frontal cortex of individuals with relapsing‐remitting (N = 26) or progressive (N = 21) multiple sclerosis or healthy control adults (N = 25) in a cross‐sectional analysis. Only individuals with progressive multiple sclerosis demonstrated reduced glutamate (F2,65 = 3.424, p = 0.04; 12.40 ± 0.62 mM versus control 13.17 ± 0.95 mM, p = 0.03) but not glutamine (F2,65 = 0.352, p = 0.7; 4.71 ± 0.35 mM versus control 4.84 ± 0.42 mM), reduced GABA (F2,65 = 3.89, p = 0.03; 1.29 ± 0.23 mM versus control 1.47 ± 0.25 mM, p = 0.05), and possibly reduced glutathione (F2,65 = 0.352, p = 0.056; 2.23 ± 0.46 mM versus control 2.51 ± 0.48 mM, p < 0.1). As a group, multiple sclerosis patients demonstrated significant negative correlations between disease duration and glutamate or GABA (ρ = −0.4, p = 0.02) but not glutamine or glutathione. Alone, only relapsing‐remitting multiple sclerosis patients exhibited a significant negative correlation between disease duration and GABA (ρ = −0.5, p = 0.03). Taken together, these results indicate that frontal cortex metabolism is differentially disturbed in progressive and relapsing‐remitting multiple sclerosis.
- 6 May 2021
- Published by Wiley in NMR in Biomedicine
- Vol. 34 (8) , e4538
Hippocampal single‐voxel MR spectroscopy with a long echo time at 3 T using semi‐LASER sequence
The hippocampus is one of the most challenging brain regions for proton MR spectroscopy (MRS) applications. Moreover, quantification of J‐coupled species such as myo‐inositol (m‐Ins) and glutamate + glutamine (Glx) is affected by the presence of macromolecular background. While long echo time (TE) MRS eliminates the macromolecules, it also decreases the m‐Ins and Glx signal and, as a result, these metabolites are studied mainly with short TE. Here, we investigate the feasibility of reproducibly measuring their concentrations at a long TE of 120 ms, using a semi‐adiabatic localization by adiabatic selective refocusing (sLASER) sequence, as this sequence was recently recommended as a standard for clinical MRS. Gradient offset‐independent adiabatic refocusing pulses were implemented, and an optimal long TE for the detection of m‐Ins and Glx was determined using the T2 relaxation times of macromolecules. Metabolite concentrations and their coefficients of variation (CVs) were obtained for a 3.4‐mL voxel centered on the left hippocampus on 3‐T MR systems at two different sites with three healthy subjects (aged 32.5 ± 10.2 years [mean ± standard deviation]) per site, with each subject scanned over two sessions, and with each session comprising three scans. Concentrations of m‐Ins, choline, creatine, Glx and N‐acetyl‐aspartate were 5.4 ± 1.5, 1.7 ± 0.2, 5.8 ± 0.3, 11.6 ± 1.2 and 5.9 ± 0.4 mM (mean ± standard deviation), respectively. Their respective mean within‐session CVs were 14.5% ± 5.9%, 6.5% ± 5.3%, 6.0% ± 3.4%, 10.6% ± 6.2% and 3.5% ± 1.4%, and their mean within‐subject CVs were 17.8% ± 18.2%, 7.5% ± 6.3%, 7.4% ± 6.4%, 12.4% ± 5.3% and 4.8% ± 3.0%. The between‐subject CVs were 25.0%, 12.3%, 5.3%, 10.7% and 6.4%, respectively. Hippocampal long‐TE sLASER single voxel spectroscopy can provide macromolecule‐independent assessment of all major metabolites including Glx and m‐Ins.
- 6 May 2021
- Published by Wiley in NMR in Biomedicine
- Vol. 34 (8) , e4538
Hippocampal single‐voxel MR spectroscopy with a long echo time at 3 T using semi‐LASER sequence
The hippocampus is one of the most challenging brain regions for proton MR spectroscopy (MRS) applications. Moreover, quantification of J‐coupled species such as myo‐inositol (m‐Ins) and glutamate + glutamine (Glx) is affected by the presence of macromolecular background. While long echo time (TE) MRS eliminates the macromolecules, it also decreases the m‐Ins and Glx signal and, as a result, these metabolites are studied mainly with short TE. Here, we investigate the feasibility of reproducibly measuring their concentrations at a long TE of 120 ms, using a semi‐adiabatic localization by adiabatic selective refocusing (sLASER) sequence, as this sequence was recently recommended as a standard for clinical MRS. Gradient offset‐independent adiabatic refocusing pulses were implemented, and an optimal long TE for the detection of m‐Ins and Glx was determined using the T2 relaxation times of macromolecules. Metabolite concentrations and their coefficients of variation (CVs) were obtained for a 3.4‐mL voxel centered on the left hippocampus on 3‐T MR systems at two different sites with three healthy subjects (aged 32.5 ± 10.2 years [mean ± standard deviation]) per site, with each subject scanned over two sessions, and with each session comprising three scans. Concentrations of m‐Ins, choline, creatine, Glx and N‐acetyl‐aspartate were 5.4 ± 1.5, 1.7 ± 0.2, 5.8 ± 0.3, 11.6 ± 1.2 and 5.9 ± 0.4 mM (mean ± standard deviation), respectively. Their respective mean within‐session CVs were 14.5% ± 5.9%, 6.5% ± 5.3%, 6.0% ± 3.4%, 10.6% ± 6.2% and 3.5% ± 1.4%, and their mean within‐subject CVs were 17.8% ± 18.2%, 7.5% ± 6.3%, 7.4% ± 6.4%, 12.4% ± 5.3% and 4.8% ± 3.0%. The between‐subject CVs were 25.0%, 12.3%, 5.3%, 10.7% and 6.4%, respectively. Hippocampal long‐TE sLASER single voxel spectroscopy can provide macromolecule‐independent assessment of all major metabolites including Glx and m‐Ins.
- Open Access
- 15 November 2019
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 10, 1173
Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker
Proton magnetic resonance spectroscopy (1H-MRS) offers a growing variety of methods for querying potential diagnostic biomarkers of multiple sclerosis in living central nervous system tissue. For the past three decades, 1H-MRS has enabled the acquisition of a rich dataset suggestive of numerous metabolic alterations in lesions, normal-appearing white matter, gray matter, and spinal cord of individuals with multiple sclerosis, but this body of information is not free of seeming internal contradiction. The use of 1H-MRS signals as diagnostic biomarkers depends on reproducible and generalizable sensitivity and specificity to disease state that can be confounded by a multitude of influences, including experiment group classification and demographics; acquisition sequence; spectral quality and quantifiability; the contribution of macromolecules and lipids to the spectroscopic baseline; spectral quantification pipeline; voxel tissue and lesion composition; T1 and T2 relaxation; B1 field characteristics; and other features of study design, spectral acquisition and processing, and metabolite quantification about which the experimenter may possess imperfect or incomplete information. The direct comparison of 1H-MRS data from individuals with and without multiple sclerosis poses a special challenge in this regard, as several lines of evidence suggest that experimental cohorts may differ significantly in some of these parameters. We review the existing findings of in vivo 1H-MRS on central nervous system metabolic abnormalities in multiple sclerosis and its subtypes within the context of study design, spectral acquisition and processing, and metabolite quantification and offer an outlook on technical considerations, including the growing use of machine learning, by future investigations into diagnostic biomarkers of multiple sclerosis measurable by 1H-MRS.
- 15 November 2019
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 10, 1173
Open AccessQuantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker
Proton magnetic resonance spectroscopy (1H-MRS) offers a growing variety of methods for querying potential diagnostic biomarkers of multiple sclerosis in living central nervous system tissue. For the past three decades, 1H-MRS has enabled the acquisition of a rich dataset suggestive of numerous metabolic alterations in lesions, normal-appearing white matter, gray matter, and spinal cord of individuals with multiple sclerosis, but this body of information is not free of seeming internal contradiction. The use of 1H-MRS signals as diagnostic biomarkers depends on reproducible and generalizable sensitivity and specificity to disease state that can be confounded by a multitude of influences, including experiment group classification and demographics; acquisition sequence; spectral quality and quantifiability; the contribution of macromolecules and lipids to the spectroscopic baseline; spectral quantification pipeline; voxel tissue and lesion composition; T1 and T2 relaxation; B1 field characteristics; and other features of study design, spectral acquisition and processing, and metabolite quantification about which the experimenter may possess imperfect or incomplete information. The direct comparison of 1H-MRS data from individuals with and without multiple sclerosis poses a special challenge in this regard, as several lines of evidence suggest that experimental cohorts may differ significantly in some of these parameters. We review the existing findings of in vivo 1H-MRS on central nervous system metabolic abnormalities in multiple sclerosis and its subtypes within the context of study design, spectral acquisition and processing, and metabolite quantification and offer an outlook on technical considerations, including the growing use of machine learning, by future investigations into diagnostic biomarkers of multiple sclerosis measurable by 1H-MRS.